
Dana-Farber’s Breast Oncology Center/X
Oct 15, 2024, 19:00
The use of TDXd for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X:
“Check out our newest treatment guideline on the use of trastuzumab deruxtecan (TDXd) for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer.”
More posts featuring Dana-Farber’s Breast Oncology Center.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 23:21
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31